Drug intelligence / Profile preview

OTX-AFS

Development stage: Discontinued
Lead developer: Ocular Therapeutix
Modality: Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
Administration: Suprachoroidal Injection

Overview

OTX-AFS is an extended-delivery formulation of aflibercept, a recombinant fusion protein used as an anti-VEGF therapy. It is designed for suprachoroidal injection and is in preclinical development by Ocular Therapeutix in collaboration with Regeneron. OTX-AFS aims to provide a sustained release of aflibercept for the treatment of retinal diseases.

Other names: aflibercept suprachoroidal injection

Targets

VEGFA (Vascular endothelial growth factor A)PGF (Placental Growth Factor)

Beyond the preview

Go deeper on OTX-AFS.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OTX-AFS.

Explore the full profile